These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26423769)

  • 1. Immunotherapy in Sarcoma: Future Horizons.
    Burgess M; Gorantla V; Weiss K; Tawbi H
    Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential for immunotherapy in soft tissue sarcoma.
    Tseng WW; Somaiah N; Engleman EG
    Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of immunotherapy for sarcoma.
    Tsukahara T; Emori M; Murata K; Mizushima E; Shibayama Y; Kubo T; Kanaseki T; Hirohashi Y; Yamashita T; Sato N; Torigoe T
    Expert Opin Biol Ther; 2016 Aug; 16(8):1049-57. PubMed ID: 27158940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of immunotherapy for the treatment of sarcoma.
    Klemen ND; Kelly CM; Bartlett EK
    J Surg Oncol; 2021 Mar; 123(3):730-738. PubMed ID: 33259653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy against sarcomas.
    Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next frontiers in systemic therapy for soft tissue sarcoma.
    Yen CC; Chen TW
    Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
    Seong G; D'Angelo SP
    Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell target antigens across major gynecologic cancers.
    Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
    Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of engineered T-cell therapy for synovial sarcoma.
    Dallos M; Tap WD; D'Angelo SP
    Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From vision to reality: deploying the immune system for treatment of sarcoma.
    Wilky BA; Goldberg JM
    Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
    Banks LB; D'Angelo SP
    J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
    Martín-Broto J; Moura DS; Van Tine BA
    Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.